Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,280 total articles
Verra Mobility's business remains high-quality: recurring government contracts, durable commercial fleet relationships, and $105M in free cash flow support a mid-term swing trade. The stock has pulled back near its 52-week low and shows oversold technicals, while valuation on EV/EBITDA (~8.7x) is reasonable versus growth profile. Enter $13.25, stop…
Acumen Pharmaceuticals (ABOS) is a clinical-stage Alzheimer’s developer with sabirnetug (ACU193) in a Phase 2 trial. Topline results from ALTITUDE-AD are expected in late 2026. With $128.4M in cash, a market cap of ~$157.5M, depressed technicals, and a relatively small float, the stock is a defined-risk way to play a positive Phase 2 readout. This …
Lumentum (LITE) is benefitting from a surge in demand for optical components tied to AI data centers and an industrial-laser cycle. Revenue is growing >90% YoY and management guided to $1B in Q4, yet the stock trades at premium multiples (P/S ~28, P/E >150, EV/EBITDA >111). This trade idea outlines a tactical long entry on weakness at $880.00 with …
Harmony Gold (HMY) is trading at $17.10 with a market cap of about $10.45B and a trailing P/E of 11.1. The company sits squarely in a gold cycle that has pushed bullion to multi-year highs, but the stock still trades well below its 52-week high of $26.06. This trade idea lays out a mid-term (45 trading days) long: entry at $17.10, target $21.00, st…
Alibaba is moving from e-commerce giant to vertically integrated AI player. Shipping 560,000 Zhenwu M890 units, rolling out the Qwen3.7-Max LLM and targeting $4.42B of recurring AI-related revenue by year-end, the company is building both the stack and the customers. This trade idea lays out an entry at $136.00, a stop at $123.00 and a long-term ta…
Broadcom's AI-facing revenue trajectory looks clearer than ever, supported by large hyperscaler deals and a ramping custom XPU footprint. The stock trades at a premium - P/E ~80 and EV/EBITDA ~55 - but free cash flow and strong returns on capital argue for absorption of current multiples over time. This trade idea buys into continued AI-driven cade…
Mondelez is set to re-rate as profitability normalizes. The company posts mid-single-digit organic growth, 18% operating margins, and a dependable dividend. With EV/EBITDA near 20 and a market cap around $79B, the market is under-pricing near-term margin tailwinds tied to easing cocoa and input costs. We recommend a long trade with entry at $61.30,…
Occidental Petroleum is shifting from rebuild to returns. Strong free cash flow from elevated oil prices, a recent $9.7B divestiture and materially lower debt give the board flexibility to increase dividends and buybacks. For active traders, a mid-term long (45 trading days) targeting $75 captures both cash-return rerating and continued strength in…
Koninklijke Philips offers a compelling risk-reward for buyers willing to back software/AI adoption and continued margin improvement. We lay out an actionable long trade with specific entry, stop and target, plus the catalysts and risks to watch.
Alphabet reported a step‑change in operating leverage in FQ1 and the market is starting to price higher quality earnings. With a $4.69T market cap, $64.4B in free cash flow, and a P/E near 30, this trade idea targets a re‑rating toward a higher multiple over the next 45 trading days, while protecting capital with a tight stop.
Novo Nordisk (NVO) is an action-worthy long here. New OASIS 4 data for the oral Wegovy pill and a materially compressed valuation versus its growth profile set up asymmetric upside. I lay out a specific entry, stop and target for a long-term trade (180 trading days), the catalysts that can re-rate the stock, and the risks that could derail the thes…
BNY Mellon Strategic Municipal Bond Fund (DSM) offers a 4.18% yield and currently trades inside its 52-week range with a price-to-book below 1. This trade idea recommends buying DSM at the current market price to capture distribution income and a likely move toward the 52-week high, while using a strict stop to limit downside if the CEF’s discount …
ARS Pharmaceuticals is a buy as improving access to Neffy and early commercial traction compress downside while creating meaningful upside over the next 3-6 months. This trade idea lays out entry/stop/targets, catalysts and risks for a position sized to biotech volatility.
Relay Therapeutics' PI3Kα inhibitor zovegalisib is showing clinical signals across vascular anomalies and breast cancer that read less like a single-drug program and more like a reusable oncology/rare-disease asset. With Breakthrough designation, expanding dose cohorts, a Pfizer supply pact for combination development, and a market cap near $2.3B, …
GH Research (GHRS) is a clinical-stage biotech developing inhaled 5-MeO-DMT (GH001) for treatment-resistant depression. Positive Phase 2b remission data and a completed response to an FDA IND hold have pushed sentiment higher. With a $1.5B market cap and shares trading near $22, the stock is a binary-but-rewarding trade if regulatory momentum conti…
Marex Group has delivered sharply higher revenues and adjusted PBT as market volatility and rising clearing client balances boost trading and clearing activity. The stock trades at ~11.7x earnings with a $3.9B market cap, leaving room for upside if volatility persists and margins hold. However, short interest, ongoing litigation, and the cyclicalit…
<p>Itafos looks cheap on headlines and balance-sheet summaries; the stock trades like a microcap whose valuation already discounts weaker fertilizer prices and project execution risk. This is a directional long: an asymmetric bet that phosphate prices and product spreads recover while management continues to demonstrate steady operating execution a…
Amazon looks mispriced to the upside. Structural strength in ads, improving unit economics in logistics as fulfillment investments roll off, and a visible capex inversion create a path to stronger free cash flow. This trade targets a rebound in multiple expansion as investors re-rate quality cash generation.
Lincoln National (LNC) trades near $34 and screens cheap on several traditional metrics - sub-1x book, mid-single-digit P/E, and a meaningful dividend yield. Market uncertainty and recent flow into retirement solutions provide catalysts that can re-rate the stock. This trade idea lays out a mid-term (45 trading days) buy plan with an exact entry, s…
MongoDB has moved from growth-only to a cash-generative, margin-improving business. The market has largely priced in the profitability arc, but near-term catalysts and strong cash flow create a favorable risk/reward for a disciplined mid-term long. Entry, stop and target laid out with explicit horizon and risk framing.
BILL Holdings is showing the early signs of a profit-first reset: revenue growth remains intact while free cash flow is healthy. With activist interest, rising transaction-fee take, and an industry-wide drive to cut costs, the market could re-rate BILL from a growth multiple to a cash-flow multiple. This trade idea buys into that re-rate over the n…
Main Street Capital (MAIN) has dropped to a valuation that underprices steady distributable income, strong credit metrics and an improving technical setup. Given its 6% yield, 16% ROE, low non-accruals reported in recent coverage and heavier short positioning, this is a tactical relative-long vs. peers such as CSWC. Trade plan included: entry $50.5…
Halozyme is transitioning from a technology licensing business into a cash-flow engine driven by royalty growth. Management raised 2026 guidance (revenue $1.71-$1.81B; royalty revenue >$1B) and is guiding to robust adjusted EBITDA and non-GAAP EPS. With free cash flow near $668M and an enterprise value of ~$9.83B, HALO offers a real re-rating oppor…
ServiceNow is trading like a fading growth story while its cash flow, enterprise momentum and an accelerating AI monetization plan argue for a multi-month recovery. Current price levels present a trade with defined risk and attractive upside if the company executes on subscription growth and margin stabilization.
Broadridge (BR) is a cash-generative market infrastructure play that processes $8 trillion in tokenized assets monthly and is layering AI automation across its middle/back-office platforms. At roughly $17.3B market cap and $150 per share, the market has discounted a multi-year growth/margin re-rating. This trade idea buys the setup for a long-term …
